Stage (next event)
Phase 2 To be Initiated
Catalyst Info & Data Links
TITLE: AGEN1181 for Advanced endometrial cancer Phase 1 Readout
WHAT IS THE NEXT CATALYST EVENT?
Phase 1 Readout
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
05-2020 (ASCO) AGEN1181, a Clinical Stage Fc-Engineered anti-CTLA-4 Antibody with Improved Therapeutic Potential for the Treatment of Patients with Advanced Malignancies. O'Day, et al.
06-2020 (AACR) Expanding the Therapeutic Potential of anti-PD-1 and anti-CTLA-4 Therapy with Innovative Fc Engineering and Rationale Combinations for the Treatment of Solid Tumors. Tanne, et al.
Mechanism of Action
To develop AGEN1181, Agenus leveraged the above discovery to modify a part of the antibody known as the Fc region, which interacts with other immune cells to enhance antitumor immunity. In pre-clinical studies, this “Fc-engineered” antibody significantly improved the cross-talk between antigen presenting cells (APCs) and T cells. In cancer immunotherapy, such an interaction is necessary to mount a potent immune response against cancer.
multifunctional Fc-engineered next generation anti-CTLA-4 antibody
Updated by MV
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post